Table 3.

Clinical trials conducted for platinum-resistant ovarian cancer.

Year	Chemotherapy regimen	Subjects	RR (%)
2006	gemcitabine + epirubicin13	30	43.3
2008	pegylated liposomal doxorubicin (biweekly)24	50	40
2008	gemcitabine + pegylated liposomal doxorubicin14	48	37.5
2009	gemcitabine + oxaliplatin17	50	37
2007	gemcitabine + cisplatin (biweekly)19	35	31.5
2007	irinotecan + doxorubicin67	13	30.8
2006	gemcitabine + pegylated liposomal doxorubicin15	30	33.3
2006	topotecan + pegylated liposomal doxorubicin26	27	28
2009	topotecan + docetaxel (weekly)68	29¶	25
2006	pegylated liposomal doxorubicin25	29	23.1
2007	paclitaxel + ifosfamide + cisplatin30	22	22.7
2005	gemcitabine + pegylated liposomal doxorubicin16	37	22
2009	pemetrexed55	51	21
2005	docetaxel + irinotecan69	30	20
2006	paclitaxel (weekly)41	48	20.9
2008	CKD-602 (camptotecan analog)58	5	20
2008	gemcitabine + topotecan21	23	17
2006	gemcitabine + cisplatin20	57	16
2007	bevacizumab50	44	15.9
2005	canfosfamide 70	34	15
2010	ixabepilone53	49	14.3
2005	9-aminocamptothecin54	56	14
2006	LY355703 (cryptophycin analog)57	24	12.5
2005	tamoxifen + goserelin59	26*	11.5
2007	carboplatin + cyclosporine + interferon-α31	30**	10
2009	pemetrexed56	91	9.9
2007	gemcitabine + oxaliplatin18	21	9.5
2008	topotecan + pegylated liposomal doxorubicin27	22	9.1
2007	pegylated liposomal doxorubicin†,12	96	8.3
2006	capecitabine71	36	7.3
2007	trabectedin72	79	6.3
2007	gemcitabine†,12	99	6.1
2005	sabarubicin73	19	5.3
2009	canfosfamide74	232	4.3
2009	capecitabine75	32	3.1
2008	letrozole76	31	3
2006	irofulven77	58	1.7
2006	imatinib mesylate78	12	0
2007	tamoxifen + gefitinib60	56	0
2007	docetaxel (weekly)44	7	0
2007	matuzumab79	30	0

Analysis of 40 clinical trials published between January 2005 and March 2010.

^†Different arms in the same study.

^¶19 out of 29 were ovarian or peritoneal cancer.

^*17 out of 26 were platinum-resistant.

^**19 out of 30 were platinum-resistant.

Abbreviations: Subjects, number of patients enrolled in the trial; and RR, response rate (complete response rate + partial response rate or objective response rate if response rate is not available).